Microtubule-binding natural products for cancer therapy
- PMID: 20577942
- DOI: 10.1055/s-0030-1250073
Microtubule-binding natural products for cancer therapy
Abstract
Natural products, especially microtubule-binding natural products, play important roles in the war against cancer. From the clinical use of vinblastine in 1961, paclitaxel in 1992, to ixabepilone in 2007, microtubule-binding natural products have continually contributed to the development of cancer therapy. The present review summarizes the development of representative microtubule-binding natural products including agents binding to the colchicine-binding site, the VINCA alkaloid-binding site, the taxane-binding site and other binding sites. Future directions for the development of new anticancer microtubule-binding natural products are discussed. Finding new formulations, new targets and new sources of microtubule-binding natural products may enable more members of this kind of agent to be introduced into the clinic for cancer therapy.
Georg Thieme Verlag KG Stuttgart-New York.
Similar articles
-
Microtubule dynamics as a target in oncology.Cancer Treat Rev. 2009 May;35(3):255-61. doi: 10.1016/j.ctrv.2008.11.001. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117686 Free PMC article. Review.
-
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017. PLoS One. 2017. PMID: 28787019 Free PMC article.
-
Ixabepilone: a new microtubule-targeting agent for breast cancer.Expert Rev Anticancer Ther. 2008 May;8(5):671-81. doi: 10.1586/14737140.8.5.671. Expert Rev Anticancer Ther. 2008. PMID: 18471040 Review.
-
Anti-Microtubule Drugs.Methods Mol Biol. 2016;1413:403-21. doi: 10.1007/978-1-4939-3542-0_25. Methods Mol Biol. 2016. PMID: 27193863 Review.
-
Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.Expert Opin Investig Drugs. 2008 Apr;17(4):523-46. doi: 10.1517/13543784.17.4.523. Expert Opin Investig Drugs. 2008. PMID: 18363517 Review.
Cited by
-
Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers.RSC Adv. 2021 Dec 13;11(63):39728-39741. doi: 10.1039/d1ra07922k. eCollection 2021 Dec 13. RSC Adv. 2021. PMID: 35494162 Free PMC article.
-
The antitumour effect of galangin and luteolin with doxorubicin on chemically induced hepatocellular carcinoma in rats.Contemp Oncol (Pozn). 2021;25(3):174-184. doi: 10.5114/wo.2021.110048. Epub 2021 Oct 14. Contemp Oncol (Pozn). 2021. PMID: 34729037 Free PMC article.
-
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6. Target Oncol. 2014. PMID: 23832397 Clinical Trial.
-
Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.Cell Oncol (Dordr). 2012 Dec;35(6):451-60. doi: 10.1007/s13402-012-0104-6. Epub 2012 Oct 3. Cell Oncol (Dordr). 2012. PMID: 23055341
-
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.J Med Chem. 2018 Sep 13;61(17):7877-7891. doi: 10.1021/acs.jmedchem.8b00827. Epub 2018 Aug 30. J Med Chem. 2018. PMID: 30122035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
